Lean machine for ADCs
SynAffix investors want ADC company to focus on platform tech, not products
Platform companies are notorious for the heavy cash required to turn their platforms into products, but SynAffix B.V. investors are taking a different tack. The syndicate in last week's series A round is hoping for a big return by keeping the company financially lean.
The plan is to focus on optimizing the biotech's ADC technology rather than putting a lot of cash into products.
On Feb. 18, SynAffix raised an undisclosed amount from Aravis; BioGeneration Ventures; MS Ventures, which is the strategic VC fund of the Merck Serono division of Merck KGaA (Xetra:MRK); and BOM Capital.
CEO Peter van de Sande said the funds would be used